

# European School of Internal Medicine in Riga 2017

**Astor Riga Hotel  
Riga, Latvia  
5-11 February 2017**

Be part of the 27th ESIM - Winter School in Riga 2017

## **Deranged liver biochemistry in asymptomatic individuals: What to do?**

**Nikolaos K. Gatselis**

Assistant Professor of Medicine

Department of Medicine and Research Lab of Internal Medicine

Larissa Medical School, Thessaly University

Internal Medicine Society of Greece



# Liver Function Tests (LFTs)

- aminotransferases (AST, ALT)
- alkaline phosphatase (ALP)
- $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GT)
- bilirubin (total, direct)
- albumin
- prothrombin time

**biochemical  
markers of  
liver injury**

**markers of  
hepatocellular  
function**



# Asymptomatic elevation of liver enzymes

- Retest to confirm the abnormal values
- Search for previous laboratory tests (how long has the elevation been present?)
- Assess the degree of elevation
- Different diagnostic algorithm of abnormal transaminases than the increase in cholestatic enzymes



# Common and rare causes of elevated transaminases (AST/ALT)

Common Causes	Relatively rare causes	Rather to extremely rare causes
Alcohol abuse	Autoimmune hepatitis	Celiac disease
Chronic hepatitis B or C	Hyperthyroidism	Addison's disease
NAFLD	Intense muscular exercise	Inherited disorders of muscle cells metabolism
Drugs, toxic substances and/or "healthy" food supplements	Wilson's disease	Acquired muscle disease (e.g. polymyositis)
	a1-antitrypsin deficiency	
	Hemochromatosis (primary or secondary)	



# Common causes of elevated cholestatic enzymes ( $\gamma$ GT/ALP)

Cholestatic diseases	Infiltrating liver diseases
Primary biliary cholangitis	Hepatocellular carcinoma
Primary or secondary sclerosing cholangitis	Metastatic liver cancer
Bile duct obstruction (partial)	Granulomatous diseases (sarcoidosis, tuberculosis, granulomatosis with polyangiitis, leprosy)
Drug induced (e.g. anabolic steroids)	Liver abscess
IgG4-related disease	Amyloidosis



***Most of the time, with history  
and physical you should have a  
good idea what's the likely  
cause of the elevated liver  
tests!***




# Aminotransferases

## AST & ALT




- Sensitive markers of hepatocellular damage
- Usually suggest necrosis of hepatocytes
- ALT: mainly produced in the liver
- AST: liver, heart, muscles, brain



# Degree of elevation of transaminases

- **<300 IU/ml**
  - alcoholic hepatitis, NAFLD, alcoholic liver disease, chronic viral hepatitis, autoimmune hepatitis
- **500 - 5000 IU/ml**
  - acute viral hepatitis, acute severe autoimmune hepatitis, drugs
- **>5000 IU/ml**
  - ischemic hepatitis, liver failure from paracetamol overdose, HSV





# Transaminases and alcohol

## A special occasion

- Vit. B6 = cofactor for AST, ALT
- ↓Vit. B6 => ↓AST, ↓↓ALT
- Alcohol transfer mAST from mitochondria to cytoplasm and thereafter to serum

AST > ALT

AST, ALT levels do not reflect the degree of damage in alcoholic liver disease

- **A (alpha) for A**
- **B (beta) for B**
- **Γ (gamma) for C**
- **Δ (delta) for D**

# Question

**Which are the normal values of transaminases:**

- A. according to each laboratory report**
- B. individualized for each patient**
- C. less than 30 IU/L for ♂ and 19 IU/L for ♀**
- D. none of the above**



# Question

**Which are the normal values of transaminases:**

- A. according to each laboratory report
- B. individualized for each patient
- C. less than 30 IU/L for ♂ and 19 IU/L for ♀**
- D. none of the above




# Diagnostic approach of asymptomatic patients with elevated transaminases

## What are the normal values?

**Clinical case**  
female 60-years-old  
no symptoms  
Hx: hypertension, DM,  
dyslipidemia  
Treatment: statin

α-αμινάση (SGOT, AST)	51	IU/l	<31
γ-αμινάση (SGPT, ALT)	51	IU/l	<34

- Chronic hepatitis C



Fibroscan: 14.6 kPa

F4 (METAVIR)

**ALREADY CIRRHOTIC!!!**



# Diagnostic approach of asymptomatic patients with elevated transaminases

What are the normal values?

- **Use only one value as ULN**
  - 40 IU/L (classical value)
  - 19 IU/L (females) & 30 IU/L (males)
  - do not rely on ULN of laboratories



# Alcohol

- Detailed history & physical examination
- AST/ALT > 2:1 (90%)
- AST < 8x & ALT < 5x or normal
- $\gamma$ GT
- macrocytosis ( $\wedge$ MCV)
- US: yes
- CT or MRI: no
- Liver biopsy is not required
- Check for HBV and HCV



parotid enlargement  
rinophyma



# Alcohol

## Clinical case

- 28-years-old-woman, kindergarten teacher
- ascites due to portal hypertension
- HBV & HCV (-)
- AST/ALT = 1:1
- Drugs (-)
- Alcohol (-)
- Investigation for:
  - AIH (-)
  - Vascular diseases (-)
  - Wilson, hemochromatosis (-)
  - rare systemic diseases (-)





# Alcohol

## Clinical case

### The question never asked...

- Question: *Do you consume alcohol?*
- Response: *No! Only whenever I go out!*
- Question: *How often do you go out?*
- Response: *Almost everyday!!!*



# Clinical case

- 45 years old South Africa man
- presents for routine physical and found to have elevated liver tests
- PMH: hyperlipidemia
- Soc: drinks 2 beers / week
- Born in South Africa, moved to the US in 1990 and lived there for 15 years
- Family history of liver disease (but he mentions that they don't go to the doctor)
- PE: normal
- AST 50, ALT 60, ALP 70, Tbili 0.5
- US normal

**Chronic hepatitis B**



# Question

A patient with chronic hepatitis B from medium or high endemic area, most likely get infected:

- A. by intravenous drug use
- B. during birth or childhood (intrafamilial spread)
- C. by sexual contact
- D. by blood transfusion




# Question

A patient with chronic hepatitis B from medium or high endemic area, most likely get infected:

- A. by intravenous drug use
- B. during birth or childhood (intrafamilial spread)**
- C. by sexual contact
- D. by blood transfusion




# HBV serologies



# Chronic hepatitis B

The importance of an early diagnosis



**DIAGNOSE AND TREAT TIMELY**



# Question

**Which the most successful way to eradicate the hepatitis delta virus:**

- A. The improvement of socioeconomic conditions**
- B. Radical vaccination against HBV**
- C. Precaution measures against HIV**
- D. A and C**



# Question

Which the most successful way to eradicate the hepatitis delta virus:

- A. The improvement of socioeconomic conditions
- B. Radical vaccination against HBV**
- C. Precaution measures against HIV
- D. A and C







# Hepatitis Delta (HDV)

This virus could infect only patients with hepatitis B.


## Hepatitis D (Delta) Virus




# Hepatitis Delta (HDV)

## Clinical course

### HBV-HDV co-infection



### HBV-HDV super-infection



# Hepatitis Delta (HDV)

## Diagnostic markers

- **anti-HDV (IgG and IgM)**
  - check in all patients with HBV infection at the beginning of follow-up and periodically thereafter
- **HDV RNA**
  - identify individuals with active HDV infection
  - decide to initiate treatment
  - monitor antiviral treatment efficacy
  - tailor treatment schedule

**DO NOT FORGET THE HEPATITIS DELTA VIRUS IN ALL  
CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS!!!**



# Clinical case

- 48 years old man is found to have abnormal liver tests on routine physical examination
- No significant previous medical history
- On no medications
- “No blood transfusions or needle use since in college”
- PE normal
- AST 62, ALT 88, ALP 75, Tbil 0.7, INR 1.0, Albumin 4.1

**Chronic hepatitis C**



# Diagnostic workup for hepatitis C

detection of **anti-HCV Abs**

**AND**


**confirmation of positive results in a 2<sup>nd</sup>  
sample**

**(sensitivity of EIA 92-97%)**




**anti-HCV (+)**


**Regardless of AST/ALT values**



**refer to Hepatology Unit**



**HCV RNA, genotype, Fibrosan<sup>®</sup>**



**treatment initiation with direct acting  
antivirals preferably**



# Viral hepatitis

## Clues from the medical history

### High risk groups


- family history (HBV)
- travel history (HAV, HEV)
- sexual history (HBV, MSM → HAV)
- origin (Asia, Africa → HBV)
- illicit drug use (HBV, HDV, HCV) (i.v. or snorted - even once)
- Hx of blood transfusion (especially before 1992)
- tatoos
- healthcare workers - needlesticks



# Hepatitis E Virus

## A old friend from the past!

Proportion of reported cases of acute viral hepatitis in Germany





# Clinical case

- 45-years-old male
- ALT: 85 , AST: 60 IU/ml (twice)
- Virology test: negative
- No alcohol consumption
- Works out 2 hours a day

**Drug induced liver injury**

- A. Acute liver injury due to extreme strength training
- B. NAFLD
- C. A laboratory error
- D. Nothing of the above



# Drugs and Toxic Substances

- **Non-steroidal anti-inflammatory drugs (NSAIDs)**
- **Antibiotics**
  - synthetic penicillin, quinolones, ketoconazole, fluconazole, isoniazid, rifampicin
- **Antiepileptics**
  - phenytoin, carbamazepine
- **Hypolipidemic (statin)**
- **Anabolic**
- **Homeopathic medicine**
- **Supplements (herbals)**
- **Toxic substances**
  - cocaine, ecstasy, LSD

**When did you start them?  
Any changes in doses?**



**LIVER BIOPSY USUALLY NOT REQUIRED  
DISCONTINUATION OF “SUSPICIOUS” AGENTS & CLOSE MONITORING**



# Question

**Which is the commonest cause of death in patients with NAFLD/NASH:**

- A. Cardiovascular diseases**
- B. Liver related complications**
- C. Neoplasia**
- D. The expected survival is similar to general population**



# Question


**Which is the commonest cause of death in patients with NAFLD/NASH:**

- A. Cardiovascular diseases**
- B. Liver related complications
- C. Neoplasia
- D. The expected survival is similar to general population






# Non-alcoholic fatty liver disease (steatosis ± steatohepatitis)

Microvesicular fatty liver



Macrovesicular fatty liver



**Fatty liver  
Steatosis**



**Non-alcoholic  
Steatohepatitis**



**Fibrosis  
Cirrhosis**

## **METABOLIC SYNDROME**

obesity  
hyperinsulinemia  
peripheral insulin resistance  
diabetes  
hypertriglyceridemia  
hypertension

**It is rather a benign  
disease**



# Non-alcoholic fatty liver disease (steatosis ± steatohepatitis)

- thorough history
- ALT > AST
- US: liver hyperechogenicity (supports clinical diagnosis)
- CT or MRI: not required
- Accurate diagnosis by liver biopsy but it is not always required





**It's a diagnosis of exclusion**



# Non-alcoholic fatty liver disease (steatosis ± steatohepatitis)


**NAFLD/NASH does not protect you from having  
another liver disease!!!**

- Hepatitis C (or B)
- Autoimmune liver disease
- Iron overload
- Cancer



# Wilson disease


- generally affects young people (<45 years old)
- hepatic/neurologic/psychiatric manifestations
- ↓ceruloplasmin
- ↑24hr urine cooper excretion
- hemolysis
- Kayser-Fleischer ring
- *ATP7B* mutations





# Hemochromatosis


- Hereditary (primary) or multiple transfusions (secondary)
- ↑ ferritin
- Transferrin saturation (serum Fe / TIBC) x 100 >40%
- **HFE genotype:** C282Y/C282Y, C282Y/H63D, H63D/H63D(?)
- Hemojuvelin, Transferrin receptor 2, Ferroportin 1



# Celiac disease

## Clinical case

- female 50-years-old (menopausal)
- transaminasemia during the last 5 years
- Hx: irritable bowel syndrome, ferrum deficiency, atrophic gastritis, Hashimoto thyroiditis
- anti-h-tTG/DGP (IgA/IgG) screen (+++)
- endoscopy: atrophy of villi
- Marsh III



# Clinical case

- 56 years old woman presents with fatigue, myalgias
- PMH: hypothyroidism, hypertension
- Meds: thyroxin, atenolol
- So: no E/D
- FHx: father with
- PE: with mild EUQ tenderness to
- ALT 245, ALB 3.8, INR 1.2, Tbil 1.8, ALP 207
- globulins 5 g/dL & IgG 2300 mg/dL
- US mild hepatomegaly

**Autoimmune hepatitis**



# Autoimmune hepatitis

## Characteristics

1. progressive liver disease
2. hypergammaglobulinemia ( $\uparrow$  IgG)
3. circulating autoantibodies
4. interface hepatitis
5. favorable response to immunosuppressive treatment


**Without treatment: 10-years survival only 10%**




# Autoimmune hepatitis

## The burden of the disease

- Under-diagnosed due to unfamiliar clinical physicians, laboratories, pathologists
- Estimate prevalence: 10-20/1000000 (Europe, N. America)
- Similar to SLE, PBC, Myasthenia Gravis



Werner M, Scand J Gastroenterol 2008



**It not only a disease of young females!!!**



# Autoimmune hepatitis

## Classification & Autoantibodies

### AIH-1

- ▶ ANA
- ▶ SMA
- ▶ ANCA
- ▶ anti - ASGP-R
- ▶ anti - SLA/LP

### AIH-2

- ▶ anti - LKM-1
- ▶ anti - LKM-3
- ▶ anti - LC1
- ▶ anti - ASGP-R



# Cholestatic enzymes

## Alkaline phosphatase (ALP)

- **liver, bone**, placenta, intestine, kidney, leucocytes
- higher in children, adolescents, pregnancy
- increase in:
  - **cholestatic syndromes**
    - level of increase does not distinguish intra- or extra-hepatic obstruction
  - **liver infiltrating diseases**
    - hepatocellular carcinoma, sarcoidosis, tuberculosis, amyloidosis, liver abscess
  - **other causes**: bone diseases with osteoblastic activity



# Cholestatic enzymes

## $\gamma$ -glutamyl transpeptidase ( $\gamma$ GT)

- liver, pancreas, spleen, heart, seminal vesicle, kidney, brain
- higher in males
- increases in:
  - pancreatic diseases, alcoholism, phenytoin or barbiturate, myocardial infarction, renal insufficiency, chronic obstructive pulmonary disease, diabetes mellitus
- a sensitive marker for liver diseases when increases in parallel with ALP






# Diagnostic approach of asymptomatic patients with elevated cholestatic enzymes

- **History and physical examination**
- **Ultrasound imaging of liver and biliary tree**



# Diagnostic approach of asymptomatic patients with elevated cholestatic enzymes



# Clinical case

- A 47 year old Caucasian female presents with complaints of itching, dry mouth, and RUQ abdominal pain. She also notices yellowish pigmentation changes on her skin. Her medical history includes frequent UTI's and

**Primary biliary cholangitis**

- ALP 350, ALT 75, ALP 350, GGT 110
- Antinuclear Antibodies (ANA) pos
- Antimitochondrial Antibodies (AMA) pos



# Question

**Which is the pathognomonic finding in primary biliary cholangitis:**

- A. increase of IgM levels**
- B. presence of antimitochondrial antibodies**
- C. presence of itching**
- D. increases of cholestatic enzymes (ALP,  $\gamma$ GT)**




# Question

Which is the pathognomonic finding in primary biliary cholangitis:

- A. increase of IgM levels
- B. presence of antimitochondrial antibodies**
- C. presence of itching
- D. increases of cholestatic enzymes (ALP,  $\gamma$ GT)






# Diagnostic approach of asymptomatic patients with elevated cholestatic enzymes



# Primary biliary cholangitis

- destruction of bile ducts
- middle aged females
- AMA (+) 95%
- ANA (+) 20%
- Clinical pattern
  - asymptomatic
  - fatigue, itching, arthralgia
  - end stage liver disease



# Clinical case


- A 55 y.o. male with history of Ulcerative Colitis presents with recurrent low-grade fevers and right upper abdominal pain associated with elevated ALP and GGT.
- ALP 250 U/L, GGT 150 U/L, bilirubin <1.0 mg/dL, INR <1.5, PT <14 sec, aPTT <35 sec, platelets >100,000/mm<sup>3</sup>, hemoglobin >10 g/dL, hemocrit >30%.
- **Primary Sclerosing Cholangitis**
- **Cholangitis**
- **Cholangitis** elevated <100





# Primary sclerosing cholangitis

- chronic cholestatic disease
- males 40-years-old
- associated with IBD in 60-80%
- asymptomatic (50%) → obstructive jaundice  
→ cirrhosis, cholangiocarcinoma
- MRCP and/or ERCP
- liver biopsy



# Deranged liver biochemistry in asymptomatic individuals

**OVERESTIMATION**

**UNDERESTIMATION**

unnecessary  
medical  
intervention

increase of  
morbidity &  
mortality due  
to ignorance



# Thank you for your attention.



© Original Artist  
Reproduction rights obtainable from  
[www.CartoonStock.com](http://www.CartoonStock.com)

